ImmuPharma (LON:IMM) Shares Up 9.5% - Should You Buy?

Key Points

• ImmuPharma's shares rose by 9.5% on Tuesday, reaching a high of GBX 14.20 after trading more than 23 million shares, which is a 176% increase from its average volume.
• The company, with a market cap of £60.47 million, reported a quarter EPS of GBX (0.38) and an expected annual EPS of -339.00.
• ImmuPharma specializes in developing peptide-based therapeutics aimed at treating autoimmune diseases, with its lead program being Lupuzor™, a treatment for Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 9.5% on Tuesday . The stock traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). 23,646,498 shares traded hands during mid-day trading, an increase of 176% from the average session volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Trading Up 9.5%

The company has a 50-day moving average price of GBX 4.46 and a two-hundred day moving average price of GBX 3.33. The stock has a market capitalization of £60.47 million, a P/E ratio of -1,359.55 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.